A small start-up in 1993, Millennium Pharmaceuticals, a biotechnology company brand by the end of 1998 with a market capitalization of 1.4 billion euros. The Cambridge-based company’s growth strategy had relied heavily on building alliances for early-stage drug discovery and licensing its gene-based technology.

A small start-up in 1993, Millennium Pharmaceuticals, a biotechnology company brand by the end of 1998 with a market capitalization of 1.4 billion euros. The Cambridge-based company’s growth strategy had relied heavily on building alliances for early-stage drug discovery and licensing its gene-based technology.
«Hide

from
Michael D. Watkins,
Sarah G. Matthews
Source: Harvard Business School
24 pages.
Publication Date: Sep 27, 1999. Prod #: 800032-PDF-ENG
Strategic deal making at Millennium Pharmaceuticals HBR case solution